利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

106 条记录 (耗时 0.05 秒)

    Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
    2.
    发明授权
    Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease 失效
    使用成纤维细胞生长因子，血管内皮生长因子和相关蛋白质治疗急性和慢性心脏病的方法

    公开(公告)号：US06759386B2

    公开(公告)日：2004-07-06

    申请号：US09828330

    申请日：2001-04-06

    申请人： Wayne P. Franco

    发明人： Wayne P. Franco

    IPC分类号： A61K3818

    CPC分类号： G01N33/6893 ,  A61K38/1825 ,  A61K38/1866 ,  G01N2800/32 ,  G01N2800/324

    摘要： Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

    摘要翻译： 本文公开了在治疗心脏病中施用生长因子蛋白质的合理的多层方法。 还公开了一种评估生长因子蛋白的施用的有效性的方法，其包括在用生长因子蛋白处理的患者中CPK-MB水平的临床测定。 此外，公开了一种治疗心脏病的方法，包括通过口服吸入治疗施用治疗有效量的生长因子蛋白质。

    Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137
    4.
    发明授权
    Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137 有权
    使用在一个或多个位置谷氨酸盐89，天冬氨酸101或亮氨酸137突变的人碱性成纤维细胞生长因子类似物的方法

    公开(公告)号：US06737404B2

    公开(公告)日：2004-05-18

    申请号：US09826210

    申请日：2001-04-05

    申请人： Barry A. Springer ,  Michael W. Pantoliano ,  Celia M. Sharp

    发明人： Barry A. Springer ,  Michael W. Pantoliano ,  Celia M. Sharp

    IPC分类号： A61K3818

    CPC分类号： C07K14/503 ,  A61K38/00

    摘要： The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

    摘要翻译： 本发明涉及具有超强调性质的人碱性成纤维细胞生长因子的新颖突变蛋白。 公开了蛋白质和各自编码的核酸物质。 本发明还体现了用于扩增所述核酸序列和产生所述突变蛋白的载体和宿主细胞。 还公开了刺激细胞分裂，治疗伤口，治疗缺血，治疗心脏病，治疗神经损伤，治疗外周血管疾病，治疗胃溃疡和治疗十二指肠溃疡的方法。

    Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
    5.
    发明授权
    Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin 有权
    非水性注射制剂，pH调节用于生长激素的延长释放

    公开(公告)号：US06664234B1

    公开(公告)日：2003-12-16

    申请号：US09894058

    申请日：2001-06-28

    申请人： Daniel N. Heintz ,  Yunhua N. Jeng

    发明人： Daniel N. Heintz ,  Yunhua N. Jeng

    IPC分类号： A61K3818

    CPC分类号： A61K38/27

    摘要： The present invention provides compositions of matter which allow for the extended release and enhanced bioavailability of biologically-active polypeptides following parenteral delivery to an animal. More particularly, it concerns compositions comprising biologically-active somatotropin formulated for extended release, methods of preparing these compositions, and methods of using the same. These compositions comprise somatotropin, a pH-adjusting constituent (PAC), and a substantially non-aqueous, hydrophobic excipient. The PAC may comprise any suitable, biocompatible compound including, but not limited to one or mixtures of two or more of the following: acetic acid, phosphoric acid, monobasic phosphate. The PAC is added to the compositions of matter in an amount effective to adjust the pH to or near to the isoelectric point (pI) of the somatotropin component.

    摘要翻译： 本发明提供了一种物质组合物，其允许在肠胃外递送至动物后延长释放并增加生物活性多肽的生物利用度。 更具体地，涉及包含用于延长释放的生物活性生长激素配制剂，制备这些组合物的方法和使用该组合物的方法的组合物。 这些组合物包含生长激素，pH调节成分（PAC）和基本上非水性疏水赋形剂。 PAC可以包括任何合适的生物相容性化合物，包括但不限于以下两种或多种的一种或多种混合物：乙酸，磷酸，一元磷酸盐。 将PAC加入到物质组合物中，其量有效地将pH调节至或接近生长激素组分的等电点（pI）。

    Folliculogenesis
    6.
    发明授权
    Folliculogenesis 失效
    卵泡发生

    公开(公告)号：US06660717B1

    公开(公告)日：2003-12-09

    申请号：US09856995

    申请日：2001-08-29

    申请人： Ursula Maria Rose ,  Marcel van Duin

    发明人： Ursula Maria Rose ,  Marcel van Duin

    IPC分类号： A61K3818

    CPC分类号： C12N5/0609 ,  A61K38/18 ,  C12N2501/19 ,  C12N2501/31 ,  C12N2517/10

    摘要： The present invention relates to the use of GDF-9 in assisted reproduction and to kits comprising GDF-9. A method is provided to stimulate follicle and oocyte development and maturation. The method comprises administering GDF-9 in combination with gonadotropins.

    摘要翻译： 本发明涉及GDF-9在辅助繁殖中的用途以及包含GDF-9的试剂盒。 提供了一种刺激卵泡和卵母细胞发育和成熟的方法。 该方法包括与促性腺激素组合施用GDF-9。

    SMDF and GGF neuregulin splice variant isoforms and uses thereof
    9.
    发明授权
    SMDF and GGF neuregulin splice variant isoforms and uses thereof 失效
    SMDF和GGF神经调节蛋白剪接变体同种型及其用途

    公开(公告)号：US06602851B1

    公开(公告)日：2003-08-05

    申请号：US09684708

    申请日：2000-10-06

    申请人： Steven L. Carroll

    发明人： Steven L. Carroll

    IPC分类号： A61K3818

    CPC分类号： C07K14/4756 ,  Y10S514/903

    摘要： Distinct cDNAs encoding six cysteine-rich domain-NRGs and four glial growth factor isoforms were identified and sequenced. Additional heterogeneity is found in the EGF-like (&agr;- and &bgr;-isoforms) and carboxy terminal (a and b variant) regions of CRD-NRGs. Furthermore, the predicted GGF proteins contain glycosylation domains previously found only in mesenchymal NRGs. GGF mRNAs accumulate in axotomized nerve, a subpopulation of DRG neurons and most spinal cord motoneurons. CRD-NRGs, however, are undetectable in injured nerve except by RT-PCR. In contrast, the majority of DRG and spinal cord motor neurons express CRD-NRGs, with a &bgr;1 isoform being most abundant and at least some of these proteins are secreted in a form capable of activating erbB receptors. Thus, GGF and CRD-NRG subfamilies are more structurally diverse than previously appreciated. NRG actions during Wallerian degeneration may be modulated by the action of distinct splice variants.

    摘要翻译： 鉴定并测序编码六个富含半胱氨酸的结构域NRG和四个胶质细胞生长因子同种型的不同的cDNA。 在CRD-NRGs的EGF样（α-和β-同种型）和羧基末端（a和b变体）区域中发现另外的异质性。 此外，预测的GGF蛋白含有之前仅在间充质NRG中发现的糖基化结构域。 GGF mRNA积聚在轴突神经中，DRG神经元和大多数脊髓运动神经元的亚群。 然而，CRD-NRGs在受损的神经中是不可检测的，除了通过RT-PCR。 相比之下，大多数DRG和脊髓运动神经元表达CRD-NRG，其中β1同种型最丰富，并且这些蛋白质中的至少一些以能够激活erbB受体的形式分泌。 因此，GGF和CRD-NRG亚家族在结构上比以前更为多样化。 Wallerian退化期间的NRG作用可能受到不同剪接变体的作用的调节。

    Tissue-derived tumor growth inhibitor
    10.
    发明授权
    Tissue-derived tumor growth inhibitor 失效
    组织来源的肿瘤生长抑制剂

    公开(公告)号：US06586394B1

    公开(公告)日：2003-07-01

    申请号：US08188197

    申请日：1994-01-27

    申请人： Kenneth K. Iwata ,  John R. Stephenson ,  Leslie I. Gold

    发明人： Kenneth K. Iwata ,  John R. Stephenson ,  Leslie I. Gold

    IPC分类号： A61K3818

    CPC分类号： C07K14/52 ,  A61K35/44 ,  A61K35/50 ,  A61K38/00 ,  C07K14/495 ,  C07K16/22 ,  C07K16/24 ,  C07K2319/00 ,  G01N33/74

    摘要： This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.

    摘要翻译： 本发明涉及具有N-末端氨基酸序列Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val的色谱回收多肽 。 该多肽称为TGI，TGI-1和TGI-2。 它也称为TGF-β3。 本发明还涉及包含色谱回收多肽的组合物。 本发明还提供了抑制上皮细胞生长或愈合伤口或治疗由色谱回收的多肽组成的烧伤的药物组合物。 本发明还涉及包括向受试者施用有效量的色谱回收的方法，从而抑制上皮细胞的生长，或愈合伤口或治疗烧伤。